

# Evidence and Coverage Decisions in Cancer A View from NCI

Martin L. Brown

[mb53o@nih.gov](mailto:mb53o@nih.gov)

Health Services and Economics Branch  
Applied Research Program  
National Cancer Institute

CMS Evidence Development and  
Coverage Advisory Committee  
Baltimore, MD  
October 22, 2007

# Topics

- Introduction to NCI Research Data and Methods
- Five Topics of Concern in Cancer
  - Cancer Screening and Surveillance
  - Increasing Cancer Prevalence, Second Cancers
  - Resource Requirements
  - High Cost Oncology Drugs, Tailored Therapy
  - Supportive Therapy
- Evidence Gaps

# Evidence Gaps

- Practice patterns and clinical outcomes in older populations not represented in clinical trials
  - Screening
  - Treatment, including tailored treatment, supportive care
  - Monitoring for recurrence
- Emerging screening modalities
  - Colorectal Cancer: CT Colonography, Immunochemical Fecal Blood Tests, Fecal DNA Tests
  - Lung Cancer: CT Screening
- Pharmaco-surveillance, -vigilance, -genomics
  - Late effects of cancer treatment (e.g. radiation, anthracyclines)
  - Beneficial/adverse effects of common drugs (e.g. HRT)
  - Clinical utility, cost-effectiveness of genomic targeted therapies and/or prognostic markers (e.g. OncoDX, Her-2-Neu, SNPS for onology drug metabolism)

## Practice patterns and clinical outcomes in older populations not represented in clinical trials

- Do adverse effects of screening and/or treatment increase with advancing age? (e.g. adverse effects of colonoscopy)
- Should increased morbidity and reduced life-expectancy inform an upper-age cut-off of treatment of screening?
- Surveillance for cancer recurrence or progression
  - can controlled trials be conducted?
  - can observational data be used to make coverage decisions?

# Emerging Screening Modalities

- Projecting beyond initial mortality endpoint trials
  - Fecal tests
  - Endoscopy and CT colonography
- Projecting from controlled trial settings to community care
  - E.g. establishing and monitoring performance and quality assurance standards (for initial screening and follow-up care) for colorectal and lung cancer screening